about
Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infectionPD-L1 Blockade Differentially Impacts Regulatory T Cells from HIV-Infected Individuals Depending on Plasma ViremiaA new multidisciplinary home care telemedicine system to monitor stable chronic human immunodeficiency virus-infected patients: a randomized studyGeneration and characterization of a defective HIV-1 Virus as an immunogen for a therapeutic vaccine.[Indicator condition guided human immunodeficiency virus requesting in primary health care: results of a collaboration].Increased alpha-defensins 1-3 production by dendritic cells in HIV-infected individuals is associated with slower disease progressionEffect of TNF-alpha genetic variants and CCR5 Delta 32 on the vulnerability to HIV-1 infection and disease progression in Caucasian Spaniards.Quinine induced lupus-like syndrome and cardiolipin antibodies.Inflammatory responses in blood samples of human immunodeficiency virus-infected patients with pulmonary infections.Protease inhibitor monotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammation.Adenosine deaminase enhances the immunogenicity of human dendritic cells from healthy and HIV-infected individuals.Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count.Use of RT-defective HIV virions: new tool to evaluate specific response in chronic asymptomatic HIV-infected individualsA dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication.Lymphoid tissue collagen deposition in HIV-infected patients correlates with the imbalance between matrix metalloproteinases and their inhibitorsA therapeutic dendritic cell-based vaccine for HIV-1 infection.Effects on innate immunity of a therapeutic dendritic cell-based vaccine for HIV-1 infectionHIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.MicroRNA Profile in CD8+ T-Lymphocytes from HIV-Infected Individuals: Relationship with Antiviral Immune Response and Disease Progression.Central nervous system opportunistic infections in developed countries in the highly active antiretroviral therapy era.Influence of episodes of intermittent viremia ("blips") on immune responses and viral load rebound in successfully treated HIV-infected patients.The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial.Rate and predictors of non-AIDS events in a cohort of HIV-infected patients with a CD4 T cell count above 500 cells/mm³.Evolution of broadly cross-reactive HIV-1-neutralizing activity: therapy-associated decline, positive association with detectable viremia, and partial restoration of B-cell subpopulationsImmune modulators and treatment interruption.Therapeutic vaccines against HIV infection.Dendritic cell based vaccines for HIV infection: the way ahead.Dendrimers as nonviral vectors in dendritic cell-based immunotherapies against human immunodeficiency virus: steps toward their clinical evaluation.Community-Acquired Pneumococcal Pneumonia in Virologically Suppressed HIV-Infected Adult Patients: A Matched Case-Control Study.Rate and predictors of progression in elite and viremic HIV-1 controllers.Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area.Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).Early Detection Of Hiv Infection And Of Asymptomatic Sexually Transmitted Infections Among Men Who Have Sex With Men.New challenges in therapeutic vaccines against HIV infection.The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens.Impact of long-term antiretroviral therapy interruption and resumption on viral reservoir in HIV-1 infected patients.Standard vaccines increase HIV-1 transcription during antiretroviral therapy.Utilization of healthcare services by people living with HIV/AIDS in Europe. Eurosupport Group.Factors associated with the immune response to hepatitis A vaccination in HIV-infected patients in the era of highly active antiretroviral therapy.
P50
Q24536249-7E8CE295-4EB5-4091-AACD-68129F5D6F7DQ28551329-820E756C-E8CB-4025-B09D-98214870B7F1Q28743362-070014C0-1685-412E-92B5-F54F7227E68DQ31106756-595B7F31-D061-4D66-99CA-D89729DF376DQ33421199-CA4DFF80-81A0-4B98-A797-91B8234B0F37Q33535953-A4F090AB-B506-4667-9227-6570BA1387FEQ33564972-6FBB4CA1-CB4A-47B5-8BF7-84B89DA85B91Q33579165-F181587E-5124-4754-8F26-8025F3B5AF17Q33711805-BD89AE2A-5192-4DD0-848F-8D771889D296Q34288534-D9DF65A1-D52D-43BF-A862-9EF25F6BEC0BQ34512293-92F5924C-C819-4536-89FE-6574AB6E330EQ34548243-27BAD135-0688-4872-A969-4D32807BE884Q34630184-79DA4FB6-55E8-4CB0-933D-DF0A7B19AAE1Q34646987-BAE86B83-5158-4FA2-9CFC-161DB072221BQ34764052-50A08076-B31B-4572-A361-BFE1A4FA5ECEQ34764392-17D7C5A2-7823-4E07-B68F-AD3DDA01EBCEQ35731394-8768E1BE-82AD-4AD3-9A67-414DA9773669Q35973632-9256864D-639C-4E6C-9D0C-47E439068D7AQ36015292-62B6E748-3C3D-4893-ADFD-A9D9BFD66B9BQ36422552-3331EA3F-ED81-4B8C-B76A-04D272A6DEDCQ36509570-E2B86F9D-C8F5-4CA1-9986-BE19F6E87CE2Q36580911-F3071BF4-6698-44A6-95E8-F3A434A9D7B7Q37025746-AA3F149E-237F-4C02-8E85-40F1189B0D44Q37254327-44600466-89D1-4269-994B-E02947E894F3Q37447549-8DDC4E24-6F69-4227-B78D-E029231B3AA1Q38013505-47EC66AA-8937-4965-B7D1-B82EF005E117Q38126373-3FBDFFDB-6DA9-4E4E-9920-E5ABCE06F030Q38296086-8AA75078-0833-4DB2-9DC1-37551AB19E9DQ38402197-9B7C880D-588A-4D2C-81E8-AE97DD4C2F3FQ38409790-B3D18725-8669-45D9-A0E9-F5DE5553C237Q38415577-E58DCE63-EC11-45EB-8C62-C8EE5D59999EQ38462726-9EBB9821-5917-4A15-A492-1A6976768C80Q38484762-EDC296CD-A6B1-44FB-9045-7C6D33EB535BQ38607131-3B791196-19B3-43C4-A242-1A6BBE1181B0Q38692205-46ECF261-FAC3-476C-A1CD-DA43DD8B1781Q38725610-72F74B74-0956-484C-93CE-1E78A53EBC28Q38738697-6C68D77B-D9D0-4933-8820-53AFC7DA574EQ38840779-F3B3A7B4-2A2F-4B67-9EE2-E2E71425E8DBQ38892546-19FDB157-E940-4747-8441-E45F9C9BC5ECQ39400490-7B74F21A-ADEF-451F-AF0B-88CA3389FA07
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Felipe García
@ast
Felipe García
@en
Felipe García
@es
Felipe García
@nl
Felipe García
@sl
type
label
Felipe García
@ast
Felipe García
@en
Felipe García
@es
Felipe García
@nl
Felipe García
@sl
prefLabel
Felipe García
@ast
Felipe García
@en
Felipe García
@es
Felipe García
@nl
Felipe García
@sl
P1053
F-4242-2014
P106
P21
P31
P3829
P496
0000-0001-7658-5832